GlassScriptPhysician profile
Ryan Keith Couvillion
NPI 1760706774
$6,434.78
in general payments reported to CMS, 2019-2025
25 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 79% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $125 · 2021: $251 · 2022: $676 · 2023: $841 · 2024: $767 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169 · Honoraria: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.01 |
| Honoraria | $975.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,586.05 | 2019-2022 | |
| Becton, Dickinson and Company | $975.00 | 2025 | |
| Abbvie INC. | $972.31 | 2023-2025 | Botox, Alloderm |
| Revance Therapeutics, INC. | $256.47 | 2024-2025 | Daxxify |
| Mentor Worldwide LLC | $185.04 | 2021 | |
| Tepha INC | $162.60 | 2019 | |
| Tela Bio, INC. | $158.24 | 2024 | Ovitex 2s |
| Galderma Laboratories, L.P. | $137.12 | 2024 | |
| Integra Lifesciences Corporation | $126.42 | 2023-2025 | Durasorb Monofilament Mesh, Integra, Omnigraft |
| Depuy Synthes Sales INC. | $112.51 | 2023 | Matrixmandible |
| Coopersurgical, INC. | $100.95 | 2020 | |
| Janssen Biotech, INC. | $95.67 | 2023-2024 | Tremfya |
| Motiva USA, LLC | $75.00 | 2025 | |
| Musculoskeletal Transplant Foundation INC. | $70.55 | 2019 | |
| Rti Surgical, INC | $67.29 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $48.96 | 2021-2022 | |
| Davol INC. | $47.73 | 2022 | |
| Ucb, INC. | $46.48 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $44.88 | 2024-2025 | |
| Heron Therapeutics, INC. | $44.79 | 2023 | Zynrelef |
| Lilly USA, LLC | $44.43 | 2021-2023 | Taltz |
| Arcutis Biotherapeutics, INC. | $23.10 | 2023 | |
| Biofrontera INC. | $19.83 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $17.18 | 2023 | |
| Leo Pharma INC. | $16.18 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Couvillion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.